{"id":5791,"date":"2019-07-01T00:00:00","date_gmt":"2019-07-01T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/"},"modified":"2023-06-14T19:58:00","modified_gmt":"2023-06-14T23:58:00","slug":"prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/","title":{"rendered":"Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013"},"content":{"rendered":"<p>Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing patterns, we conducted a cohort study of adults &#x2265;66 years of age in Ontario, Canada, with MAC or Mycobacterium xenopi PD during 2001&#x2013;2013. Using linked laboratory and health administrative databases, we studied the first treatment episode (&#x2265;60 continuous days of &#x2265;1 of a macrolide, ethambutol, rifamycin, fluoroquinolone, linezolid, inhaled amikacin, or, for M. xenopi, isoniazid). Treatment was prescribed for 24% MAC and 15% of M. xenopi PD patients. Most commonly prescribed was the recommended combination of macrolide, ethambutol, and rifamycin, for 47% of MAC and 36% of M. xenopi PD patients. Among MAC PD patients, 20% received macrolide monotherapy and 33% received regimens associated with emergent macrolide resistance. Although the most commonly prescribed regimen was guidelines-recommended, many regimens prescribed for MAC PD were associated with emergent macrolide resistance.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing patterns, we conducted a cohort study of adults &#x2265;66 years of age in Ontario, Canada, with MAC or Mycobacterium xenopi PD during 2001&#x2013;2013. Using linked laboratory and health administrative databases, we studied the first treatment episode [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[],"migration-helper-qa-sample-set":[],"class_list":["post-5791","journal_article","type-journal_article","status-publish","hentry"],"acf":{"citation":"Brode SK, Chung H, Campitelli MA, Kwong JC, Marchand-Austin A, Winthrop KL, Jamieson FB, Marras TK. <em>Emerg Infect Dis<\/em>. 2019; 25(7):1271-80. Epub 2019 Jul 1.","source_url":"https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/7\/18-1817_article","ices_scientist":[1158,1207,1149],"site":[6733],"research_program":[],"news_release":[],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"9ADB9411-E908-421A-BED6-B494DD5947CA","sitecore_item_name":"Prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease","sitecore_field_values":"{\n  \"Title\": \"Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013\",\n  \"Short title\": \"Prescribing patterns for treatment of\",\n  \"Summary\": \"Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). This study sought to determine prescribing patterns.\",\n  \"Citation\": \"<p>Brode SK, Chung H, Campitelli MA, Kwong JC, Marchand-Austin A, Winthrop KL, Jamieson FB, Marras TK. <em>Emerg Infect Dis<\/em>. 2019; 25(7):1271-80. Epub 2019 Jul 1. DOI: <a href=\"http:\/\/doi.org\/10.3201\/eid2507.181817\" title=\"opens external link\">https:\/\/doi.org\/10.3201\/eid2507.181817<\/a><\/p>\",\n  \"Abstract\": \"<p>Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing patterns, we conducted a cohort study of adults &ge;66 years of age in Ontario, Canada, with MAC or Mycobacterium xenopi PD during 2001&ndash;2013. Using linked laboratory and health administrative databases, we studied the first treatment episode (&ge;60 continuous days of &ge;1 of a macrolide, ethambutol, rifamycin, fluoroquinolone, linezolid, inhaled amikacin, or, for M. xenopi, isoniazid). Treatment was prescribed for 24% MAC and 15% of M. xenopi PD patients. Most commonly prescribed was the recommended combination of macrolide, ethambutol, and rifamycin, for 47% of MAC and 36% of M. xenopi PD patients. Among MAC PD patients, 20% received macrolide monotherapy and 33% received regimens associated with emergent macrolide resistance. Although the most commonly prescribed regimen was guidelines-recommended, many regimens prescribed for MAC PD were associated with emergent macrolide resistance.<\/p>n<p><a href=\"https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/7\/18-1817_article\" title=\"Opens external link\">View full text<\/a><\/p>\",\n  \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n  \"ICES Scientists\": \"{75FA159D-7A26-4F9B-B257-39A8B29EE0A0}|{A63E52B6-A1CB-4479-9F43-492E65695C5B}|{14489280-87E2-4E37-BCF5-35BDF557014F}\",\n  \"Posted Date\": \"20190701T000000\",\n  \"Show on Publications Landing Page\": \"1\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2019\/July\/Prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013<\/title>\n<meta name=\"description\" content=\"Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013\" \/>\n<meta property=\"og:description\" content=\"Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T23:58:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\\\/\",\"name\":\"ICES | Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2019-07-01T04:00:00+00:00\",\"dateModified\":\"2023-06-14T23:58:00+00:00\",\"description\":\"Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013","description":"Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013","og_description":"Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T23:58:00+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/","name":"ICES | Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2019-07-01T04:00:00+00:00","dateModified":"2023-06-14T23:58:00+00:00","description":"Surveys suggest that clinicians diverge from guidelines when treating Mycobacterium avium complex (MAC) pulmonary disease (PD). To determine prescribing","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/prescribing-patterns-for-treatment-of-mycobacterium-avium-complex-and-m-xenopi-pulmonary-disease-in-ontario-canada-2001-2013\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Prescribing patterns for treatment of Mycobacterium avium complex and M. xenopi pulmonary disease in Ontario, Canada, 2001\u20132013"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/5791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1149"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1207"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1158"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=5791"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=5791"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=5791"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=5791"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=5791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}